TORREGROSA, Cecile; PERNOT, Simon; VAFLARD, Pauline; PERRET, Audrey; TOURNIGAND, Christophe; RANDRIAN, Violaine; DOAT, Solene; NEUZILLET, Cindy; MOULIN, Valerie; STOUVENOT, Morgane; ROTH, Gael; DARBAS, Tiffany; AUBERGER, Benjamin; GODET, Tiphaine; JAFFRELOT, Marion; LAMBERT, Aurelien; DUBREUIL, Olivier; GLUSZAK, Cassandre; BERNARD-TESSIER, Alice; TURPIN, Anthony; PALMIERI, Lola-Jade; BOUCHE, Olivier; GOUJON, Gael; LECOMTE, Thierry; SEFRIOUI, David; LOCHER, Christophe; GRADOS, Lucien; GIGNOUX, Pauline; TRAGER, Stephanie; NASSIF, Elise; SAINT, Angelique; HAMMEL, Pascal; LECAILLE, Cedric; BUREAU, Mathilde; PERRIER, Marine; BOTSEN, Damien; BOURGEOIS, Vincent; TAIEB, Julien; AUCLIN, Edouard

doi:10.1002/ijc.34166

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

International Journal of Cancer. 2022, vol. 151, n° 11, p. 1978-1988

Résumé en anglais

After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR + PR + SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2 years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2 months, median OS was 13.0 months (95% CI: 11.3-14.7) and 10.4 months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P < .0001). Median PFS was 6.0 months (95% CI: 5.4-6.5) and 5.1 months (95% CI: 4.3-5.6) (P < .0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P = .0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.< Réduire

Mots clés en anglais

aflibercept

bevacizumab

chemotherapy

metastatic colorectal cancer

Métadonnées

Partager cette publication !

Licence d’utilisation du document

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche